VivoSeq
Musculoskeletal

Tibia Fracture

6

Pipeline Programs

2

Active Trials

6

Companies Involved

Tibia Fracture is an early-stage landscape with 6 programs across 6 companies. The most active players are Hyundai Pharmaceutical Co., LTD., EMD Serono, Kenvue Brands. 2 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

25/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

8

clinical trials

Unknown status2 · 25%
Completed2 · 25%
Recruiting1 · 13%
Terminated1 · 13%
Withdrawn1 · 13%
Not yet recruiting1 · 13%

Trial Activity

8 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)